ATE389652T1 - Benzothiazol-derivate als liganden des adenosinrezeptors - Google Patents

Benzothiazol-derivate als liganden des adenosinrezeptors

Info

Publication number
ATE389652T1
ATE389652T1 AT04732950T AT04732950T ATE389652T1 AT E389652 T1 ATE389652 T1 AT E389652T1 AT 04732950 T AT04732950 T AT 04732950T AT 04732950 T AT04732950 T AT 04732950T AT E389652 T1 ATE389652 T1 AT E389652T1
Authority
AT
Austria
Prior art keywords
ligands
adenosine receptor
benzothiazole derivatives
benzothiazole
derivatives
Prior art date
Application number
AT04732950T
Other languages
English (en)
Inventor
Alexander Flohr
Roland Jakob-Roetne
Roger Norcross
Claus Riemer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE389652T1 publication Critical patent/ATE389652T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT04732950T 2003-05-19 2004-05-14 Benzothiazol-derivate als liganden des adenosinrezeptors ATE389652T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03011039 2003-05-19

Publications (1)

Publication Number Publication Date
ATE389652T1 true ATE389652T1 (de) 2008-04-15

Family

ID=33442729

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04732950T ATE389652T1 (de) 2003-05-19 2004-05-14 Benzothiazol-derivate als liganden des adenosinrezeptors

Country Status (27)

Country Link
US (1) US7371748B2 (de)
EP (1) EP1636223B1 (de)
JP (1) JP4444290B2 (de)
KR (1) KR100859886B1 (de)
CN (1) CN100528871C (de)
AR (1) AR044362A1 (de)
AT (1) ATE389652T1 (de)
AU (1) AU2004251814B2 (de)
BR (1) BRPI0410440A (de)
CA (1) CA2524366C (de)
CL (1) CL2004001067A1 (de)
CO (1) CO5630031A2 (de)
DE (1) DE602004012555T2 (de)
DK (1) DK1636223T3 (de)
ES (1) ES2301991T3 (de)
HR (1) HRP20080207T3 (de)
IL (1) IL171686A (de)
MX (1) MXPA05012360A (de)
NO (1) NO20055150L (de)
NZ (1) NZ543074A (de)
PL (1) PL1636223T3 (de)
PT (1) PT1636223E (de)
RU (1) RU2351597C2 (de)
SI (1) SI1636223T1 (de)
TW (1) TW200505882A (de)
WO (1) WO2005000842A1 (de)
ZA (1) ZA200509294B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008052930A2 (en) * 2006-11-03 2008-05-08 F. Hoffmann-La Roche Ag Preparation of 4-alk0xy-7- (tetrahydropyran-4-yl) benzothiazol-2-amine derivatives
WO2019025099A1 (en) * 2017-08-01 2019-02-07 Merck Patent Gmbh THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS
KR20200043433A (ko) 2017-08-21 2020-04-27 메르크 파텐트 게엠베하 아데노신 수용체 길항제로서의 벤즈이미다졸 유도체
KR20200043434A (ko) * 2017-08-21 2020-04-27 메르크 파텐트 게엠베하 아데노신 수용체 길항제로서의 퀴녹살린 유도체
WO2019141096A1 (zh) * 2018-01-19 2019-07-25 四川科伦博泰生物医药股份有限公司 取代脲类化合物及其制备方法和用途
EP3870294A1 (de) 2018-10-25 2021-09-01 Merck Patent GmbH 5-azaindazol-derivate als adenosinrezeptorantagonisten
KR20210083287A (ko) 2018-10-25 2021-07-06 메르크 파텐트 게엠베하 아데노신 수용체 안타고니스트로서의 5-아자인다졸 유도체
AR117844A1 (es) 2019-01-22 2021-09-01 Merck Patent Gmbh Derivados de tiazolopiridina como antagonistas del receptor de adenosina

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI91859C (fi) * 1987-06-17 1994-08-25 Eisai Co Ltd Analogiamenetelmä antiallergisena aineena aktiivisen bentsotiatsolijohdannaisen valmistamiseksi
IL90337A0 (en) * 1988-05-24 1989-12-15 Pfizer Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents
RU2251419C2 (ru) * 2000-06-21 2005-05-10 Ф. Хоффманн-Ля Рош Аг Производные бензотиазола
MXPA04004982A (es) * 2001-11-27 2004-08-11 Hoffmann La Roche Derivados de benzotiazol.
US6727247B2 (en) * 2001-12-10 2004-04-27 Hoffman-La Roche Inc. Substituted benzothiazole amide derivatives
US6734179B2 (en) * 2001-12-12 2004-05-11 Hoffmann-La Roche Inc. Benzothiazoles
CN100406446C (zh) * 2003-01-13 2008-07-30 弗·哈夫曼-拉罗切有限公司 苯并唑衍生物及其作为腺苷受体配体的用途

Also Published As

Publication number Publication date
RU2351597C2 (ru) 2009-04-10
NO20055150L (no) 2005-11-04
CN1791600A (zh) 2006-06-21
WO2005000842A1 (en) 2005-01-06
EP1636223B1 (de) 2008-03-19
DE602004012555D1 (de) 2008-04-30
DK1636223T3 (da) 2008-06-23
MXPA05012360A (es) 2006-02-02
HRP20080207T3 (en) 2008-06-30
AU2004251814A1 (en) 2005-01-06
CA2524366C (en) 2012-03-13
US20040235915A1 (en) 2004-11-25
SI1636223T1 (sl) 2008-06-30
ES2301991T3 (es) 2008-07-01
ZA200509294B (en) 2006-10-25
US7371748B2 (en) 2008-05-13
CO5630031A2 (es) 2006-04-28
KR100859886B1 (ko) 2008-09-23
TW200505882A (en) 2005-02-16
AR044362A1 (es) 2005-09-07
HK1092469A1 (zh) 2007-02-09
IL171686A (en) 2011-11-30
KR20060013406A (ko) 2006-02-09
PT1636223E (pt) 2008-05-06
BRPI0410440A (pt) 2006-06-06
EP1636223A1 (de) 2006-03-22
CA2524366A1 (en) 2005-01-06
JP2006528220A (ja) 2006-12-14
NZ543074A (en) 2009-01-31
JP4444290B2 (ja) 2010-03-31
RU2005139527A (ru) 2006-07-27
CL2004001067A1 (es) 2005-04-15
PL1636223T3 (pl) 2008-07-31
AU2004251814B2 (en) 2009-07-23
CN100528871C (zh) 2009-08-19
DE602004012555T2 (de) 2009-04-16

Similar Documents

Publication Publication Date Title
DE602004015724D1 (de) Diazepinoindolderivate als kinaseinhibitoren
DE602004024420D1 (de) Chinazolinderivate als antitumormittel
ATE491707T1 (de) Als liganden des histamin-h3-rezeptors geeignete tetrahydronaphthyridinderivate
ATE338041T1 (de) Thiazolderivate als phosphodiesterase iv- inhibtoren
ATE497953T1 (de) Thiazolderivate als modulatoren des cannabinoidrezeptors
DK1594840T3 (da) Piperidin-benzensulfonamid-derivater
DE602005027307D1 (de) Arylanilinderivate als agonisten des beta2-adrenergen rezeptors
ATE352550T1 (de) Chinazolinderivate
LTC1633724I2 (lt) Ftalazinono dariniai
ATE420066T1 (de) Amidoacetonitrilderivate
ATE306265T1 (de) Benzothiazolderivate als adenosin-rezeptor- liganden
ATE395345T1 (de) Imidazol-4-yl-ethynyl-pyridin-derivate
IS8180A (is) Nýjar besímídasólafleiður
DE602004014772D1 (de) Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors
DK1682129T3 (da) N-thiazol-2-ylbenzamidderivater
DE60305058D1 (de) Imidazoquinoline derivate als adenosine a3 rezeptor liganden
DE602004007387D1 (de) 5-substituierte chinazolinonderivate
ATE394372T1 (de) G-lactamderivate als prostaglandinagonisten
ATE449064T1 (de) Amidoacetonitrilderivate
FR2878850B1 (fr) Derives de l'inositol-1-phosphate
DE602004012555D1 (de) Benzothiazol-derivate als liganden des adenosinrezeptors
IS8045A (is) Púrín-6-ón-afleiður
DE60328233D1 (de) Sulfamatbenzothiophenderivate als steroidsulfataseinhibitoren
EP1594875A4 (de) Porphyrinderivate
ATE370947T1 (de) 7-((1,4)dioxan-2-yl)-benzothiazol derivative als adenosin-rezeptoren liganden

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1636223

Country of ref document: EP